To determine the impact of single and cumulative doses of MultiHance on toxicity, pharmacokinetics, tissue gadolinium presence, behavior and neurological function in juvenile rats. Juvenile male and female rats received either physiological saline or MultiHance at 0.6, 1.25 or 2.5 mmol/kg bodyweight. Animals received either single or six consecutive MultiHance administrations and were sacrificed the day after the last administration or after a 60-day treatment-free period. Animals were assessed for behavior, cognitive function, grip strength, gait, pupillary reflex, and auditory reflex, as well as for physical development, sexual maturation and histopathology. Gadolinium presence in brain, femur, kidneys, liver and skin was determined using inductively coupled plasmamass spectrometry (ICP-MS). No effects of MultiHance on behavior, cognitive function or any other parameter were noted, even for the highest administered cumulative dose (15 mmol/kg). Gadolinium presence was variable across tissues and decreased during the 60-day treatment-free period. The highest levels were noted in the femur and the lowest levels in the brain. Gadolinium presence in juvenile rat brain following single or repeated MultiHance administrations was minimal and non-impactful.
Introduction
Gadobenate dimeglumine (MultiHance ® ) is a gadolinium-based contrast agent (GBCA) that differs from other GBCAs approved for extracellular contrast-enhanced magnetic resonance imaging (MRI) applications in possessing markedly higher r1 relaxivity in vivo (Shen et al., 2015) . This higher relaxivity reflects weak, transient interaction of the gadobenate molecule with serum proteins, which leads to increased signal intensity (SI) enhancement relative to that seen with comparator GBCAs at equivalent dose (Giesel et al., 2006) . Numerous intra-individual comparative studies across a range of applications have shown that the greater SI enhancement achievable with gadobenate translates into significantly improved imaging and diagnostic performance (Seidl et al., 2012; Vaneckova et al., 2015; Martincich et al., 2011; Gerretsen et al., 2010) . A benefit of the greater SI enhancement achievable is that the dose of gadobenate administered can be reduced without loss of diagnostic performance relative to that achievable with standard doses of other approved GBCAs (Vaneckova et al., 2015; Balci et al., 2006; Schneider et al., 2003; Crisi et al., 2017; Khouri Chalouhi et al., 2014) . Following initial reports of increased SI in the brain (principally the dentate nucleus [DN] and globus pallidus [GP] ) on unenhanced T1-weighted images following multiple injections of GBCAs (Kanda et al., 2014; Quattrocchi et al., 2015; Radbruch et al., 2015) , numerous studies have looked to evaluate the extent and possible consequences of retained gadolinium (Gd) in the body. Non-clinical prospective studies in healthy rats have looked at the effect of repeat Gd administrations at doses that are claimed to result in patterns of Gd deposition in the cerebellum resembling those observed in human brain (Robert et al., 2015 (Robert et al., , 2016 . However, this model does not account for possible human pathologic conditions that may increase the passage of GBCAs through a compromised blood-brain barrier (BBB).
It is known that the BBB in neonatal rats is not completely formed until approximately 21 days after birth (post-natal day 21 [PND21]) (Semple et al., 2016) . The four-fold aim of our study in neonatal and juvenile rats was a) to assess systemic exposure after a single intravenous administration of gadobenate at PND10 and following intravenous administrations every four days from PND10 to PND30; b) to determine the levels of Gd deposited in target organs (liver, skin, femur, kidneys, cerebral cortex, subcortical brain and cerebellum, including the dentate nucleus); c) to evaluate the regression of any signs of toxicity during a 60-day treatment-free period; d) to monitor development up to sexual maturity. Particular attention was given to monitoring any behavioral changes and to the histopathological examination of different brain areas.
Materials and methods

Study design
This study was designed to compare the effects in juvenile SpragueDawley rats of single and repeat administrations of three doses of gadobenate dimeglumine with and without a 60-day treatment-free period relative to findings in control animals given single and repeat administrations of 0.9% physiological saline. The study was sponsored by Bracco Imaging SpA, Milan, Italy, and was conducted at the Charles River Test Facility, Lyon, France, in compliance with National and International Good Laboratory Practice (GLP) regulations.
Animals and doses
Lactating female Sprague-Dawley rats, each with a reconstituted litter of at least 5 male and 5 female pups, arrived at the Test Facility on PND7. The animal age at initiation of treatment was PND10. Table 1 provides a summary of the assignment of pups to dose groups and treatment subgroups while Fig. 1 shows schematically the treatment timeline.
Gadobenate was administered intravenously at doses of 0.6, 1.25 or 2.5 mmol/kg per administration. Control animals received 0.9% physiological saline (NaCl) at the highest administered volume of gadobenate dimeglumine (5 mL/kg). The highest dose (2.5 mmol/kg bodyweight) is the maximum practical dose based on gadobenate concentration (0.5 M) and dose volume (5 mL/kg) by the route of administration for the neonatal rat. The lower doses were selected to establish a dose-effect relationship for any potential treatment-related findings. The lowest dose (0.6 mmol/kg bodyweight) is equivalent to the usual human dose of gadobenate (0.1 mmol/kg bodyweight), after adjustment for body surface area, as recommended by the U.S. Food and Drug Administration (US FDA guidance for industry).
Animals assigned to each group (i.e. to receive single or multiple administrations of 0, 0.6, 1.25 or 2.5 mmol/kg gadobenate) were randomized to one of four treatment subgroups: animals in subgroup A were given a single administration on PND10 followed by a 60-day treatment-free period before sacrifice on PND71/72; animals in subgroup B received administrations on PND10, 14, 18, 22, 26 and 30 before sacrifice on PND31; animals in subgroup C likewise received administrations on PND10, 14, 18, 22, 26 and 30 but were sacrificed on PND91/92 after a 60-day treatment-free period; animals in subgroup D received a single administration on PND10 and were sacrificed immediately on PND11. The total cumulative dose given to animals in subgroups B and C were 3.6, 7.5 and 15 mmol/kg bodyweight. All pups from a single litter were treated at the same dose level (i.e. received injections of saline or gadobenate at doses of 0.6, 1.25 or 2.5 mmol/kg).
In all cases, gadobenate dimeglumine was administered intravenously by slow bolus injection using a pump system with a sterile syringe and needle. On the first day of dosing (PND10), injections were made into a jugular vein. Subsequent administrations to animals in subgroups B and C were into the tail vein.
Toxicokinetic (TK) evaluation was performed after a single administration to animals in subgroup D or after repeated administrations to animals in subgroup C, after the last administration on PND30.
Observations
All animals were observed at least twice daily. During the treatment period, the animals were observed before and at least once after dosing to detect any clinical signs or reactions to treatment. A full clinical examination was performed at least once weekly. Indirect ophthalmoscopy was performed during the last week of the treatment-free period, for animals in groups 1 and 4, subgroups A and C to detect abnormalities in adnexa, optic media or fundus.
All pups were weighed twice weekly up to PND22 for subgroup A and up to PND30 for subgroups B and C and then weekly up to termination for subgroups A and C. Food consumption was measured twice weekly starting after weaning for each cage of animals up to PND30 and then once weekly up to termination for subgroups A and C. The length of the left tibia of each pup in subgroups A, B and C was measured weekly from PND10 to termination. Examination of physical development and maturation, including pinna unfolding, eye opening and incisor eruption, was performed in all animals of subgroups A, B and C. Sexual maturation in females was examined from PND28 to detect the day of vaginal opening; the animals' bodyweight was recorded on the day of occurrence. Vaginal smears were examined daily for all females from the date of onset of vaginal patency until the date of the first cornified smear; the time interval between the two events was recorded. Vaginal smears were also taken daily for 2 weeks prior to sacrifice from PND77 and used to determine the estrus stage for each female before necropsy. Males were examined from PND38 to detect the day of balanopreputial skinfold cleavage; the animals' bodyweight was recorded on the day of occurrence. Sperm analysis was performed for all subgroup C males at terminal necropsy (from the left testis after removal of the tunica albuginea). Sperm counts and motility were assessed using IVOS automated equipment (Hamilton Thorne, Beverly, MA, USA). The left cauda epididymis was sampled and used for assessment of sperm motility.
Clinical laboratory tests included hematology, coagulation, serum clinical chemistry and urine analyses. They were performed on 6 animals/sex at each dose level in subgroups A, B and C on the day of necropsy, i.e., at PDN71/72, PND31/32 and PND91/92 for subgroups A, B and C, respectively.
Behavioral tests were performed on subgroup C animals as reported in Table 2 .
Determination of gadobenic acid in rat plasma by LC-MS/MS
Analysis of plasma samples from sacrificed animals was performed by Charles River Laboratories Den Bosch BV, The Netherlands. Blood samples were collected in tubes containing lithium heparin as anticoagulant and centrifuged at 1800 g, at approximately +4°C for 10 min, within 1 h after blood sampling. Plasma samples were stored frozen (between −15 and −25°C) before analysis.
Plasma samples were thawed at room temperature and prepared for liquid chromatography mass spectrometry (LC-MS/MS) analysis using an internally validated analytical method. Ten μL of plasma sample was added to 150 μL of acetonitrile/water (90:10) positioned in a 96-well Protein Precipitation Plate (Isolute ® PPT+; Biotage), mixed and eluted by centrifugation (5 min at 2000 g). Fifty μL of filtrate was then pipetted into a 2 mL 96-well plate. To this 350 μL of water was added and mixed. The mixture was injected into the LC-MS/MS system, which was composed of an Aquity UPLC system (Waters, Milford, MA, USA) and an API 5000 mass spectrometer detector (Applied Biosystems, Foster City, CA, USA). Calibration curves spanning the concentration range from 2.00 to 600 μg/mL for the analyte in rat plasma were obtained by quadratic regression analysis with a 1/x 2 weighting factor. Quality Control samples at three concentration levels were analyzed in duplicate in each analytical run. Plasma samples were analyzed for pharmacokinetic parameters (C max , T max , AUC last , t 1/2 ) and correlated with sex, dose and time (single and repeated dose). 
Determination of gadolinium by ICP-MS
Analysis of Gd in organ samples was performed using inductively coupled plasma-mass spectrometry (ICP-MS) by LabAnalysis S.r.l., Italy, in compliance with the national GLP regulatory standards applicable to the Test Site.
Excised tissue samples of brain (cerebellum, cerebral cortex, subcortical brain), femur, kidneys, liver and skin were weighed and stored at −20°C until analysis. Homogenized samples were diluted with a 4:1 mixture of 69% nitric acid and 37% hydrochloric acid (total volume 5 or 10 mL, depending on sample size), then mineralized for 180 min at 130°C, in a DigiBlock ED36S (Labtech, Hopkinton, MA, USA). The digested solutions were diluted to 25 or 50 mL with purified water, filtered and then analyzed by ICP-MS (Spectrometer model 7700×; Agilent, Santa Clara, CA, USA). Calibration curves were based on seven reference solutions that spanned the following concentration ranges: 0-25 μg/L for brain and femur; 0-30 μg/L for kidneys; 0-80 μg/L for liver and skin. These reference ranges allowed Gd determination in the range from 0.5 to 51 nmol/g for rat brain (cerebellum, cerebral cortex, subcortical brain), kidney, liver and skin and from 1.0 to 102 nmol/g for femur. Under the adopted conditions, the Lower Limit of Quantification (LLOQ) was 0.5 nmol/g tissue for brain, kidney, liver and skin, and 1.0 nmol/g for femur.
Pathology
All animals from subgroups A, B and C were fasted overnight and weighed before sacrifice. Animals were sacrificed by an intraperitoneal injection of sodium pentobarbitone (CEVA Santé Animale; Libourne, France) followed by carbon dioxide inhalation and exsanguination. Complete histopathological examination of liver, skin, kidneys, bone and brain was performed for all animals.
Brain was sampled according to STP recommended practices (Bolon et al., 2013) . Each brain was sectioned and examined at 6 levels, including the cerebral cortex, subcortical nuclei and cerebellum. Particular care was taken to examine the dentate nuclei. Histological evaluation of the stomach (hematoxylin eosin and Von Kossa staining) was performed for animals administered the intermediate dose (1.25 mmol/ kg) in subgroup B and in treated females from subgroup C. Bone marrow smears were prepared and examined at the scheduled necropsy for all animals. The testes were examined microscopically using standard hematoxylin eosin staining. A detailed qualitative examination of the testes, including tubular stages of the spermatogenic cycle, was performed for all males in subgroup C. Qualitative examination of the ovaries for developmental and other lesions was performed in all females in subgroup C. A pathology peer review was conducted by an appropriately experienced pathologist nominated by the Test Facility.
Data analysis
The effects of single and repeat administrations of gadobenate dimeglumine were evaluated relative to findings for concurrent control animals and historical data from control animals. Findings for bodyweight, bodyweight gain, food consumption, tibia length, sexual maturation, estrus cycle, sperm analysis, water maze test, open field test, gripping test, hematology, coagulation, serum clinical chemistry parameters, quantitative urinary parameters, terminal bodyweight, organ weight and tissue sample weight were reported as arithmetic mean and standard deviation calculated for each group and sex. The following parameters were analyzed statistically by subgroup for males and females separately: bodyweight and bodyweight gain, food consumption, tibia length, sexual maturation, gripping test, hematology, coagulation and serum clinical chemistry parameters, urinary parameters, bone marrow smears, terminal body weight, absolute and relative organ weight, tissue sample weight, and Gd content in organs.
Statistical analyses were performed by the Provantis ® data acquisition system (Instem; Staffordshire, UK) as follows: the best transformation for the data (none, log or rank) was determined depending upon the kurtosis of the data, the probability of the Bartlett's test for homogeneity of the variances and the similarity of the group sizes. Non-or log-transformed data were analyzed by parametric methods. Rank transformed data were analyzed using non-parametric methods. The homogeneity of means was assessed by analysis of variance (ANOVA). Data were then analyzed to test for a dose-related trend to detect the lowest dose at which there was a significant effect, based on the Williams' test for parametric data or Shirley's test for nonparametric data. If no trend was found but the means were not homogeneous, the data were analyzed by a stepwise parametric or nonparametric Dunnett's test to look for significant differences from the control group. Mean cage food consumption was analyzed using Dunnett's test alone. Data from the behavioral tests (water maze, open field), as well as findings for cornified cells, estrus cycle and sperm analysis, were analyzed using a SAS software package. Total Gd content in tissues was analyzed using a SAS software package by the Test Facility. Levene's test was used to test the equality of variance across groups and Shapiro-Wilk's test was used to assess the normality of the data distribution in each group. Data with homogeneous variances and normal distribution across all groups were analyzed using ANOVA followed by Dunnett's test. Data showing non-homogeneous variances or a non-normal distribution in at least one group were analyzed using the Kruskal-Wallis test followed by Wilcoxon's rank sum test.
Results
Gadobenate dimeglumine was administered to neonatal and juvenile rats up to 6 times in the first 30 days of their life, at doses equivalent to 4 times, twice or the standard adult human dose. No animals died and no clinical signs or symptoms were noted that could directly be attributed to gadobenate administration. One female rat from subgroup C died on PND15 just after administration of a 2.5 mmol/kg dose. However, the cause of death was accidental due to handling during the administration. No gadobenate-related changes in ophthalmology were observed irrespective of the treatment regimen. No treatment-related changes were noted in behavior (water maze and open field tests) or in Functional Observation Battery (FOB) assessment.
Bodyweight and food consumption
No differences in mean bodyweight or bodyweight gain compared to control animals were noted for animals in subgroup A (single dose, with recovery). Compared to concurrent controls, slightly lower bodyweight gains during the dosing period were noted for animals in subgroups B and C (repeated doses, without/with recovery) given gadobenate at 1.25 and/or 2.5 mmol/kg/adm. However, animals in subgroup C fully recovered bodyweight by the end of the treatment-free period. Given their low magnitude and complete reversibility, the minor variations in bodyweight gain were not considered meaningful.
There were no treatment-related changes in food consumption. Minor and transient variations in food consumption were noted for two groups of animals of differing sex but these were not considered relevant due to their low incidence and severity.
Physical development and sexual maturation
In subgroups A and C there were no obvious changes in tibia length or in reflex assessments on the days of pinna unfolding, eye opening and incisor eruption compared with controls. In subgroup B (repeated injections, no recovery) there were minimal but statistically significant lower mean values for tibia length for male and female rats given 2.5 mmol/kg/adm and female rats given 1.25 mmol/kg/adm. However, since similar changes were not observed at the same dose levels and same time points for animals in subgroup C (repeated injections, with recovery), subjected to the same treatment, the relationship of these findings to treatment remains uncertain.
A 2-day delay in eye opening compared with controls was noted for males in subgroup B given repeat doses of 2.5 mmol/kg/adm. However, since the pupil reflex was normal for all animals and in the absence of similar variations for animals in subgroup C at the same dose levels, this finding was considered to be unrelated to gadobenate administration.
A 3-day delay in mean vaginal opening for females and in preputial cleavage for males was noted for animals in subgroup C given 2.5 mmol/kg/adm. However, individual days of occurrence were still within the concurrent control range for both sexes, apart from in the case of one male. The delay had no impact on the occurrence of cornified cells in female animals. Therefore, these findings were not considered to be toxicologically relevant. No treatment related changes were found in estrus data or sperm analysis.
Hematology, serum clinical chemistry and urine analysis
There were no differences in hematology parameters among animals in subgroup C relative to control animals at the end of the treatmentfree period. Compared with controls, there were lower mean values for red blood cell parameters (red blood cell count, hemoglobin and packed cell volume) in females in subgroup A at the end of the treatment-free period, after a single administration of 2.5 mmol/kg/adm, and in males and females in subgroup B at the end of the treatment period, after repeated administrations of 1.25 mmol/kg/adm and, to a lesser extent, 2.5 mmol/kg/adm. However, the absence of treatment-related hematological differences in subgroup C animals at the end of the treatmentfree period indicated reversibility of the variations observed in subgroup B animals.
Minor serum clinical chemistry changes were noted only for subgroup B animals given 2.5 mmol/kg/adm (low zinc and triglyceride levels in both sexes and high urea levels in males) and 1.25 mmol/kg/ adm (low triglyceride levels in females only). Since these changes were not observed in subgroup C animals at the end of the treatment-free period, they were considered reversible and of no clinical relevance.
Urinalysis revealed slightly higher values for zinc concentration and/or excretion in both sexes at all dose levels at the end of the dosing period for subgroup B animals and slightly low values for sodium, chloride and calcium concentration and/or excretion for males given 1.25 and 2.5 mmol/kg/adm. These changes were not considered meaningful and, with the exception of changes in calcium, were not observed in subgroup C animals at the end of the treatment-free period. The slightly lower calcium concentration among animals in subgroup C was not considered meaningful due to the absence of other associated changes in urinalysis at the end of the treatment-free period.
Pharmacokinetics
No major sex-related differences in C max or AUC last were observed either on PND10 or PND30 (Table 3 ). The half-life values on PND10 ranged between 0.72 and 0.98 h indicating relatively rapid elimination of gadobenate ion. Based on AUC last , a decrease in gadobenate ion systemic exposure was observed between PND10 and PND30, indicating more rapid elimination on PND30 than on PND10, possibly reflecting maturation of kidney function and thus an improvement of the elimination mechanism. On PND30 the increase in AUC last was linear and dose-proportional between 0.6 and 2.5 mmol/kg/adm, for both sexes. The same correlation was not clear on PND10, due to greater data variability.
Gadolinium content
The highest levels of Gd were found in animals in subgroups D and B that received single or repeat administrations of gadobenate without a treatment-free recovery period. The highest Gd content was in the kidneys, followed by liver, femur and skin (Table 4 ). The lowest levels were found in brain areas, with no differences noted between cerebral cortex, subcortical brain and cerebellum (Fig. 2) . All Gd levels increased linearly with increasing dose. No differences in Gd content were observed between males and females.
Comparison of animals in subgroups B and C (repeated dose without and with recovery, respectively) revealed a decrease of up to 4.5-fold in Gd content in the cerebral cortex and cerebellum but less so in the subcortical brain following the 60-day treatment-free recovery period for all administered doses. The effect of the recovery period on Gd concentration in the different CNS regions of male rats, and the dosedependence profile, are demonstrated in Fig. 2 . Similar findings were obtained for female animals. Comparison of animals in subgroups A and D (single dose with and without recovery, respectively) revealed a much more evident decrease of Gd content in all brain areas (up to 33.5-fold in the cerebellum) following the 60-day recovery period.
Gd was not measurable in the brain areas of animals in the control group except for 6 out of a total of 36 samples in subgroup C. This may have been due to cross contamination, which sometimes occurs in this kind of study (Robert et al., 2015 (Robert et al., , 2016 .
The Gd content among animals in subgroup A given gadobenate at 0.6 mmol/kg bodyweight was below the level of quantification in all The area under the plasma concentration-time curve from the time of dosing to the last quantifiable concentration was calculated using the linear up/logarithmic down trapezoidal rule. At least 3 consecutive quantifiable concentrations were required for AUC calculation. The pharmacokinetic parameters were determined from the mean plasma concentrations by non-compartmental analysis, using Kinetica™ 4.4.1 (Thermo Scientific; Philadelphia, USA). b No half-life could be calculated for females given 2.5 mmol/kg/adm on PND10 since fewer than 3 time-points were determined in the elimination phase. Table 4 Mean Gadolinium content in selected organs and brain areas. SG BLQ: all individual contents below the limit of quantification (kidneys, liver and skin: < 0.5 nmol/g; femur: < 1 nmol/g). Individual contents below the quantification limit were considered equal to 0 for mean calculation. (1): 1/6 values below quantification limit; (2): 2/6 values below quantification limit; (3): 3/6 values below quantification limit; (4): 4/6 values below quantification limit; (5): 5/6 values below quantification limit.
*p < .05; # p < .01; p: probability of being equal to zero.
brain areas as well as in the kidneys, liver and skin. At higher doses the Gd content was below the level of quantification in the liver and skin. The Gd content was similarly below the level of quantification in the liver and skin of animals in subgroup C given repeated doses of gadobenate at 0.6 mmol/kg/adm. At higher doses, by far the highest levels of Gd were noted in the femur (Table 4) .
Pathology
Single or repeated intravenous administration of gadobenate, with or without a treatment-free period, did not induce macroscopic or organ weight changes at any dose level. Histologically, minimal or slight multifocal vacuolation of the corticotubular epithelium in the kidneys was noted, with dose-related observations for females at all dose levels and for males only at 1.25 and 2.5 mmol/kg/adm in subgroup B. This finding was not accompanied by degenerative or necrotic changes in epithelial cells and thus was classified as non-adverse. In subgroup C, this finding was observed only among females given 1.25 or 2.5 mmol/kg/adm, but with a lower incidence than among females from subgroup B that had not had the treatment-free period. These observations suggest an almost complete reversibility of the finding. In the stomach, minimal or slight mineralized foci in the glandular part were noted in subgroup B animals of both sexes given 2.5 mmol/kg/ adm, with a lower incidence noted at 1.25 or 0.6 mmol/kg/adm. Mineralized foci were also observed among animals in subgroup C but with a lower incidence and severity than among animals in subgroup B, again indicating partial recovery. Minimal to slight perivascular hemorrhage or perivascular inflammation was noted at injection sites in subgroup B animals of both sexes at the highest dose (2.5 mmol/kg/ adm). Although these findings were noted in only 3 of 15 animals they were not seen in any of the control animals and therefore were considered treatment-related. In animals from subgroup C, following the recovery period, no histological changes were noted at the tail vein, indicating a complete reversibility of these findings. The observations in the kidneys, stomach and at the injection site were considered examples of the non-adverse histological changes that might be expected after repeat intravenous administrations of GBCAs. No treatment-related findings were noted in the kidneys and stomach among animals in subgroup A.
The brains were sectioned and examined at 6 levels, including cerebral cortex, subcortical nuclei and cerebellum (with emphasis on the dentate nuclei). No evidence of treatment-related microscopic findings was noted at any dose level in any subgroup and no differences with control animals were observed.
Discussion
Data on the use of GBCAs for enhanced MRI of neonates and infants under 2 years of age is comparatively sparse compared with the volume of data available on enhanced imaging of adult subjects. In part, this reflects greater caution and regulatory authority limitations on the use of these agents in pediatric subjects due to a perceived heightened risk of Nephrogenic Systemic Fibrosis (NSF) among subjects with immature or developing renal function (European Medicines Agency, 2010). Although a recent study suggests that neonates receiving standard inpatient care are not at increased risk for developing renal toxicity or NSF due to administration of intravenous GBCAs (Bedoya et al., 2017) , reports of Gd retention in body and particularly brain tissues following GBCA exposure (McDonald et al., 2015; Murata et al., 2016) have nevertheless further fueled concern that pediatric subjects may be at increased risk since very young subjects also present an immature BBB (Saunders et al., 2012) . The concern is that administered GBCAs may more readily pass an under-developed BBB potentially leading to more pronounced Gd retention than might otherwise occur in patients with a fully developed BBB. Although data on gadobenate in pediatric subjects are somewhat limited at present, a recent prospective study that measured signal changes on unenhanced T1-weighted images as potentially indicative of Gd retention in the brain found no evidence of signal enhancement even after as many as 15 gadobenate administrations (Schneider et al., 2017) .
In the absence of infant human models of BBB breakdown or underdevelopment, juvenile animal models potentially provide useful information on predisposition for Gd retention following GBCA administration. To date, most studies that have investigated the effects of repeated/high dose administrations of GBCAs in animal models have utilized mature rats and have shown Gd retention patterns that are similar to those seen in humans (Robert et al., 2015 (Robert et al., , 2016 Jost et al., 2016; Jost et al., 2017; Lohrke et al., 2017; Rasschaert et al., 2017; Wáng et al., 2015; Frenzel et al., 2017; Fretellier et al., 2015; Smith et al., 2017; McDonald et al., 2017) . Comparatively few studies have been performed in neonatal/juvenile rats and those that have been performed have not directly investigated the levels of Gd retention in CNS tissues (Giorgi et al., 2015; Fretellier et al., 2014) .
As might be expected, our study revealed marked differences in pharmacokinetics between PND10 and PND30. On PND10, after a single dose of MultiHance, gadobenate ion was eliminated relatively rapidly as indicated by half-life values of between 0.72 and 0.98 h. These values compare favorably with values of 1.01-1.20 h reported for the macrocyclic agent gadoterate meglumine (Giorgi et al., 2015) and likely reflect the additional hepatobiliary clearance that occurs with gadobenate (Lorusso et al., 1999) . It is likely the additional hepatobiliary elimination would contribute to a greater extent in juvenile animals that have incomplete renal function. Notably, compensatory elimination of gadobenate ion by the renal and hepatobiliary pathways has recently been demonstrated in rat models of biliary and renal insufficiency, respectively (Kirchin et al., 2015) . Based on values for AUC last , a decrease in gadobenate ion systemic exposure was observed between PND10 and PND30. This implies more rapid elimination on PND30 than on PND10 reflecting maturation of kidney function and thus an overall improvement of the elimination mechanism.
Gd retention
It has been known for several years that Gd from both macrocyclic and linear GBCAs is retained in human bone tissue following intravenous administration (Gibby et al., 2004; White et al., 2006) . More recently, due to the exquisite sensitivity of modern analytical techniques, human autopsy series have revealed Gd deposits in numerous human tissues even after just a single dose of either linear or macrocyclic GBCAs (McDonald et al., 2015; Murata et al., 2016) . Studies in animals have likewise reported Gd deposits in both brain and body tissues Jost et al., 2017; Rasschaert et al., 2017; Wáng et al., 2015; Frenzel et al., 2017; Pietsch et al., 2009; Smith et al., 2017) . Most recently, McDonald et al. reported retained Gd in the DN, kidney, liver and spleen of adult rats at 7 days post-cumulative exposure to both macrocyclic and linear GBCAs and found differences not only between the two classes of GBCA (macrocyclic and linear) but also between GBCAs within each class (McDonald et al., 2017) . With regards to gadobenate, McDonald et al. found markedly lower Gd concentrations for this GBCA compared to that found for gadodiamide in all tissues evaluated.
Our study revealed Gd in rat brain, liver, kidneys, skin and femur, which is consistent with findings for other GBCAs in animal models. In the brain, Gd content was relatively similar in the cerebral cortex, subcortical brain and cerebellum, and increased linearly with increasing dose. At the end of the recovery period, Gd levels that were below the LLOQ were found in all brain areas of animals receiving a single gadobenate administration of 0.6 mmol/kg bodyweight. In animals receiving repeated administrations of higher doses, with or without the 60-day treatment-free period, Gd content ranged from 2 to 6 nmol/g tissue. The Gd content in the cerebellum after the treatmentfree period ranged between 0.8 and 2 nmol/g tissue, which corresponds to values found by Robert et al., (2016) . after repeated administrations of gadobenate to healthy adult rats (1.21 ± 0.48 nmol/g). These findings support the hypothesis that GBCAs do not enter the brain through a potentially leaky blood-brain barrier, but may have access to brain parenchyma through the cerebrospinal fluid, as suggested by Jost et al., (2016) . Notably, the highest values (10-20 nmol/g tissue) were found in animals treated once and sacrificed the day after dosing, which suggests still incomplete elimination from the blood. Importantly, the 60-day treatment free recovery period following repeat gadobenate administrations led to decreases in Gd levels in the cerebellum for all doses tested. This finding strongly suggests that Gd deposition might be a reversible process, at least to some extent. In the case of gadobenate, which is unique in possessing an aromatic substituent on the ligand molecule, which has been shown to facilitate its interaction with serum albumin (Cavagna et al., 1997; Giesel et al., 2006) , it is conceivable that the traces of Gd remaining in tissues after the 60-day recovery period are due to protein-bound gadobenate. This species is likely more slowly washed off than the non protein-binding linear and macrocyclic GBCAs and therefore, at late time points, may result in a higher fraction of macromolecule-associated Gd, as found by Frenzel et al. This does not imply, as suggested by those authors , that Gd is released and transferred to other ligands.
Concerning Gd retention in the kidneys, it is well-known that complete renal function is not achieved in rats until at least PND11 while in humans it is considered complete before birth, after about 35 weeks of gestation (Zoetis and Hurtt, 2003) . As expected, we found relatively high levels immediately after administration (single or repeat dose administrations; subgroups B and D), while dramatically lower levels were noted after the 60-day treatment-free period (less than 0.5% remained for the high dose group). Notably, the residual concentrations found in these latter animals (2.25/3.98 nmol Gd/g wet tissue; males/ females, respectively), were markedly lower than those found in a similar study with gadoterate meglumine (9.8 nmol Gd/g wet tissue [Giorgi et al., 2015] ). Similar findings were noted in the liver; despite the markedly increased clearance of gadobenate by the liver in rats (Lorusso et al., 1999; Kirchin et al., 2015) Gd was not detected (< 0.5 nmol/g wet tissue) with either the standard or intermediate doses after the 60-day treatment-free period. Only after repeated administrations of the high dose was a very low Gd concentration measured in the liver of female rats (0.84 ± 0.27 nmol/g wet tissue). It has been known for many years that Gd is retained in the skin of adult rats after cumulative exposure to GBCAs (Pietsch et al., 2009 ). Gd concentrations determined at time-points up to approximately one year after cumulative exposure to 12.5 mmol/kg bodyweight of GBCA revealed a plateauing from initial higher Gd levels for all agents, with final measured Gd concentrations varying with the type of GBCA administered. Notably, the highest concentration was noted for the nonionic linear agent gadodiamide (72.2 ± 11.9 nmol/g skin) while the lowest concentrations were noted for the macrocyclic agents (0.06 ± 0.03, 0.08 ± 0.02, and 0.22 ± 0.17, for gadobutrol, gadoteridol and gadoterate meglumine, respectively). The Gd concentration determined for gadobenate dimeglumine (1.4 ± 0.4 nmol/g skin) more closely resembled the concentrations determined for the macrocyclic agents than the concentration determined for gadodiamide and for the other ionic, linear agent tested, gadopentetate dimeglumine (8.5 ± 1.5 nmol/g skin). After the 60-day treatment-free recovery period, we were able to detect very low Gd concentrations (0.67 ± 0.11 and 1.22 ± 0.36, male and female animals, respectively) only after repeated administrations of the highest dose for a total cumulative dose of 15 mmol/kg bodyweight; no Gd was detected (below the LLOQ; < 0.5 nmol/g tissue) in the skin of animals that received multiple administrations of the standard and intermediate doses.
It is well-known that Gd is retained in bones, and that there are differences between GBCAs in the amount of Gd retained (Gibby et al., 2004; White et al., 2006) . It is possible that retention occurs because Gd ions, in view of their similarity to calcium ions, possess a similar capacity to form hydroxyapatite-like compounds (Darrah et al., 2009 ). In our study the Gd levels determined in the femur were the highest among all the samples analyzed after the recovery period; Gd was present in the femurs of all animal subgroups, albeit not in all individual samples. Notably, the Gd concentrations determined in animals after the 60-day treatment-free period were markedly lower than the concentrations determined in animals sacrificed immediately after dosing. This was noted both for animals that received only a single dose (0.26-2.51 vs. 7.34-47.2 nmol/g; with vs. without a recovery period, respectively) and for animals that received repeated doses (9.74-28.6 vs. 21.7-78.0 nmol/g; with vs. without a recovery period, respectively).
Rats demonstrate nearly exponential growth in bone formation and elongation, which is directly linked to their sexual maturation. Their high bone-forming activity makes study of Gd deposition in the bones of juvenile animals potentially very interesting. However, since sexual maturation, with concomitant bone growth, is much faster in rats compared with humans (Horton et al., 2008) , data obtained in animal species should be interpreted with caution when considering the human situation. For example, whereas the gonads are quiescent until puberty and spermatogenesis only begins at puberty in humans, spermatogenesis begins at about PND5 in rats and is complete at PND43 (McCormick et al., 2016) . Thus, the rat age at PND25-42 is considered analogous to 10-18 years in humans. This very rapid sexual maturation in rats, with concomitant bone formation and elongation, represents a weakness of the juvenile rat model when compared with children below 2 years of age. As a consequence, the Gd content in the bones of juvenile rats cannot be considered representative of the situation in children below 2 years of age, where slower bone formation and elongation may result in comparatively lower Gd absorption.
Observational changes
The effects of Gd retention in brain and body tissues are as yet unknown although increasing scientific evidence suggests there may be none (Welk et al., 2016; Eisele et al., 2017) . Given that the cerebellum is deeply involved in movement regulation and cognitive function (Houk and Miller, 2003) , an important objective of our study was to evaluate the effects of single and repeat administrations of gadobenate on rat locomotor and cognitive abilities. Despite extensive FOB testing on PND36 (during week 4, after the last dosing) and PND85, involving assessment of grip strength, gait, pupillary reflex, auditory reflex, as well as water maze and open field evaluations, no effect of gadobenate dosing was observed. Just one statistical variation in grip strength was noted for female animals given 2.5 mmol/kg/adm on PMD36, but this was considered unrelated to gadobenate administration due to the minimal magnitude of the change. It is worth noting that effects on locomotor activity and grip strength were apparent when other metals of environmental origin were fed with water to neonate/juvenile rats at concentrations frequently occurring in groundwater sources of India (Rai et al., 2010) . In this case, the accumulated brain levels of lead, cadmium, and arsenic were up to 40 times lower than the average Gd levels found in our study. These findings suggest that Gd deposits do not have neurotoxic effects on juvenile rats even at concentrations that are considerably higher than those of other metals of environmental origin.
Similarly, no effects of gadobenate administration were observed on the sexual maturation of animals in our study. Metals such as cadmium or lead are known to interfere with sexual maturation through both chronic and acute exposure (Pillet et al., 2005; Apostoli et al., 1998) . However, we noted no effects of either single or repeat gadobenate doses, apart from a minor 3-day delay in sexual maturation among animals in subgroup C given the highest administered dose (2.5 mmol/ kg/adm). Notably, adverse effects on reproduction have typically only been reported in rodents when the change in puberty onset is one week or more (Gray, 1991) .
Regarding histopathologic assessments, slight histological changes were found in the kidneys, stomach and at injection sites, the latter being completely reversible. These findings were considered part of the non-adverse histological changes that would be expected after repeated intravenous GBCA administration. Previous studies have shown similar histology changes in the organs of adult rats treated at comparable high doses (Harpur et al., 1993; Morisetti et al., 1999; Steger-Hartmann et al., 2010) .
Conclusions
In conclusion, the toxicity profile of MultiHance in juvenile rats after intravenous administration is similar to that observed in adult rats. No significant treatment-related effects on gross pathology, development, sexual maturation or laboratory parameters were observed up to a dose of 2.5 mmol/kg bodyweight per administration (4 times the recommended human dose). Slight histological changes in the kidneys, stomach and at injection sites occurred after repeated administrations but were considered expected non-adverse histological changes induced by GBCAs, as has been observed in adult rats. Systemic exposure to gadobenate ion decreased from PND10 to PND30, possibly reflecting maturation of kidney function and more rapid clearance. In terms of Gd presence, the highest Gd content was detected in the kidneys, followed by liver, femur, skin, and brain (cerebellum) the day after a single administration of a 2.5 mmol/kg dose. After a 60-day treatment-free period these values had decreased by more than 95%. A similar decrease in Gd content was observed in adult animals receiving repeated administrations. Importantly, no behavioral or neurological effects related to potential Gd presence in the brain were detected after single or repeated administrations up to a cumulative dose of 15 mmol/ kg bodyweight (i.e., corresponding to about 25 injections of the standard dose in humans).
